JP2017114880A5 - - Google Patents

Download PDF

Info

Publication number
JP2017114880A5
JP2017114880A5 JP2017020756A JP2017020756A JP2017114880A5 JP 2017114880 A5 JP2017114880 A5 JP 2017114880A5 JP 2017020756 A JP2017020756 A JP 2017020756A JP 2017020756 A JP2017020756 A JP 2017020756A JP 2017114880 A5 JP2017114880 A5 JP 2017114880A5
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
cycloalkyl
heterocycloalkyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017020756A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017114880A (ja
JP6501209B2 (ja
Filing date
Publication date
Priority claimed from US13/460,524 external-priority patent/US8501724B1/en
Application filed filed Critical
Publication of JP2017114880A publication Critical patent/JP2017114880A/ja
Publication of JP2017114880A5 publication Critical patent/JP2017114880A5/ja
Application granted granted Critical
Publication of JP6501209B2 publication Critical patent/JP6501209B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017020756A 2012-01-31 2017-02-07 キナーゼ阻害剤としてのプリノン化合物 Expired - Fee Related JP6501209B2 (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261593146P 2012-01-31 2012-01-31
US61/593,146 2012-01-31
US201261637765P 2012-04-24 2012-04-24
US61/637,765 2012-04-24
US13/460,524 2012-04-30
US13/460,524 US8501724B1 (en) 2012-01-31 2012-04-30 Purinone compounds as kinase inhibitors

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2014555678A Division JP6095075B2 (ja) 2012-01-31 2013-01-30 キナーゼ阻害剤としてのプリノン化合物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018228582A Division JP2019059758A (ja) 2012-01-31 2018-12-05 キナーゼ阻害剤としてのプリノン化合物

Publications (3)

Publication Number Publication Date
JP2017114880A JP2017114880A (ja) 2017-06-29
JP2017114880A5 true JP2017114880A5 (enExample) 2018-01-25
JP6501209B2 JP6501209B2 (ja) 2019-04-17

Family

ID=48870746

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014555678A Expired - Fee Related JP6095075B2 (ja) 2012-01-31 2013-01-30 キナーゼ阻害剤としてのプリノン化合物
JP2017020756A Expired - Fee Related JP6501209B2 (ja) 2012-01-31 2017-02-07 キナーゼ阻害剤としてのプリノン化合物
JP2018228582A Pending JP2019059758A (ja) 2012-01-31 2018-12-05 キナーゼ阻害剤としてのプリノン化合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2014555678A Expired - Fee Related JP6095075B2 (ja) 2012-01-31 2013-01-30 キナーゼ阻害剤としてのプリノン化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018228582A Pending JP2019059758A (ja) 2012-01-31 2018-12-05 キナーゼ阻害剤としてのプリノン化合物

Country Status (14)

Country Link
US (3) US8501724B1 (enExample)
EP (2) EP3147285A3 (enExample)
JP (3) JP6095075B2 (enExample)
KR (2) KR20180030730A (enExample)
CN (2) CN104640861B (enExample)
AU (3) AU2013215166B2 (enExample)
BR (1) BR112014018728A8 (enExample)
CA (2) CA2940039A1 (enExample)
HK (1) HK1203489A1 (enExample)
IL (1) IL261282A (enExample)
MX (1) MX2014009219A (enExample)
PH (1) PH12014501815B1 (enExample)
RU (2) RU2018118216A (enExample)
WO (1) WO2013116382A1 (enExample)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2526933T3 (pl) 2006-09-22 2015-08-31 Pharmacyclics Llc Inhibitory kinazy tyrozynowej Brutona
US20120101113A1 (en) 2007-03-28 2012-04-26 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
CA2730930C (en) 2008-07-16 2015-01-13 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
NZ772688A (en) 2010-06-03 2022-09-30 Pharmacyclics Llc The use of inhibitors of bruton’s tyrosine kinase (btk)
WO2012158795A1 (en) 2011-05-17 2012-11-22 Principia Biopharma Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
EA025496B1 (ru) 2011-05-17 2016-12-30 Принсипиа Биофарма Инк. Ингибиторы тирозинкиназы
EA201490265A1 (ru) 2011-07-13 2014-12-30 Фармасайкликс, Инк. Ингибиторы тирозинкиназы брутона
EP2734205B1 (en) 2011-07-21 2018-03-21 Tolero Pharmaceuticals, Inc. Heterocyclic protein kinase inhibitors
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
US8501724B1 (en) * 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
WO2013184572A1 (en) 2012-06-04 2013-12-12 Pharmacyclics, Inc. Crystalline forms of a bruton's tyrosine kinase inhibitor
AU2013293087B2 (en) 2012-07-24 2017-08-31 Pharmacyclics Llc Mutations associated with resistance to inhibitors of Bruton's tyrosine kinase (BTK)
US9266895B2 (en) 2012-09-10 2016-02-23 Principia Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidines as kinase inhibitors
SG11201503842PA (en) 2012-11-15 2015-06-29 Pharmacyclics Inc Pyrrolopyrimidine compounds as kinase inhibitors
US20140142099A1 (en) * 2012-11-20 2014-05-22 Principia Biopharma Inc. Purinone Derivatives as Tyrosine Kinase Inhibitors
JP6433974B2 (ja) 2013-03-14 2018-12-05 トレロ ファーマシューティカルズ, インコーポレイテッド Jak2およびalk2阻害剤およびその使用方法
EP2983674A4 (en) 2013-04-08 2017-05-10 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
US8957080B2 (en) 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
US9637487B2 (en) * 2013-07-02 2017-05-02 Pharmacyclics Llc Purinone compounds as kinase inhibitors
US9421208B2 (en) 2013-08-02 2016-08-23 Pharmacyclics Llc Methods for the treatment of solid tumors
EP3033079B1 (en) 2013-08-12 2018-10-31 Pharmacyclics LLC Methods for the treatment of her2 amplified cancer
CA2925124A1 (en) 2013-09-30 2015-04-02 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
EP4681737A3 (en) 2014-02-21 2026-03-11 Principia Biopharma Inc. Salts and solid form of a btk inhibitor
CA2942528A1 (en) 2014-03-20 2015-09-24 Pharmacyclics Inc. Phospholipase c gamma 2 and resistance associated mutations
WO2015151006A1 (en) * 2014-03-29 2015-10-08 Lupin Limited Substituted purine compounds as btk inhibitors
CA2959602A1 (en) 2014-08-01 2016-02-04 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
US9545407B2 (en) 2014-08-07 2017-01-17 Pharmacyclics Llc Formulations of a bruton's tyrosine kinase inhibitor
US10485797B2 (en) 2014-12-18 2019-11-26 Principia Biopharma Inc. Treatment of pemphigus
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
EP3303334B1 (en) 2015-06-03 2021-06-02 Principia Biopharma Inc. Tyrosine kinase inhibitors
TW201718572A (zh) 2015-06-24 2017-06-01 普林斯匹亞生物製藥公司 酪胺酸激酶抑制劑
CN105753863B (zh) * 2015-09-11 2018-07-31 东莞市真兴贝特医药技术有限公司 氧代二氢咪唑并吡啶类化合物及其应用
WO2017066014A1 (en) 2015-10-14 2017-04-20 Sunnylife Pharma Inc. Bruton's tyrosine kinase inhibitors
EP3377493B1 (en) 2015-11-20 2020-04-08 Forma Therapeutics, Inc. Purinones as ubiquitin-specific protease 1 inhibitors
RS63609B1 (sr) 2016-04-15 2022-10-31 Cancer Research Tech Ltd Heterociklična jedinjenja kao inhibitori ret kinaze
EP3442980B1 (en) 2016-04-15 2021-06-09 Cancer Research Technology Limited Heterocyclic compounds as ret kinase inhibitors
IL293621B2 (en) 2016-06-29 2023-09-01 Principia Biopharma Inc Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[4,3-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4 -Methyl-4-[4-(oxane-3-yl)piperazine-1-yl)penta-2-ananitrile
PE20190476A1 (es) * 2016-08-29 2019-04-04 Hoffmann La Roche Compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infeccion virica
CN106588937B (zh) 2017-01-16 2018-09-21 东莞市真兴贝特医药技术有限公司 咪唑并吡嗪类化合物及其制备方法和应用
AR110998A1 (es) 2017-02-24 2019-05-22 Gilead Sciences Inc Inhibidores de la tirosina cinasa de bruton
WO2018156901A1 (en) 2017-02-24 2018-08-30 Gilead Sciences, Inc. Inhibitors of bruton's tyrosine kinase
GB201705971D0 (en) 2017-04-13 2017-05-31 Cancer Res Tech Ltd Inhibitor compounds
CN109111446B (zh) 2017-06-22 2021-11-30 上海度德医药科技有限公司 一种具有药物活性的杂芳基化合物
BR112020020246A8 (pt) 2018-04-05 2022-10-18 Sumitomo Dainippon Pharma Oncology Inc Inibidores de cinase axl e uso dos mesmos
CA3095580A1 (en) 2018-04-13 2019-10-17 Sumitomo Dainippon Pharma Oncology, Inc. Pim kinase inhibitors for treatment of myeloproliferative neoplasms and fibrosis associated with cancer
WO2020023910A1 (en) 2018-07-26 2020-01-30 Tolero Pharmaceuticals, Inc. Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
CN110964016B (zh) * 2018-09-29 2021-05-28 南京药捷安康生物科技有限公司 氨基降茨烷衍生物及其制备方法与应用
AU2020221247B2 (en) 2019-02-12 2024-12-12 Sumitomo Pharma America, Inc. Formulations comprising heterocyclic protein kinase inhibitors
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
JP7795454B2 (ja) 2019-10-14 2026-01-07 プリンシピア バイオファーマ インコーポレイテッド (r)-2-[3-[4-アミノ-3-(2-フルオロ-4-フェノキシ-フェニル)ピラゾロ[3,4-d]ピリミジン-1-イル]ピペリジン-1-カルボニル]-4-メチル-4-[4-(オキセタン-3-イル)ピペラジン-1-イル]ペンタ-2-エンニトリルを投与することにより免疫性血小板減少症を治療する方法
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
KR20220130179A (ko) 2020-01-20 2022-09-26 젠자임 코포레이션 재발성 다발성 경화증(rms)에 대한 치료용 티로신 키나제 저해제
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
AU2021209884A1 (en) 2020-01-22 2022-09-15 Principia Biopharma Inc. Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
KR102577689B1 (ko) 2020-05-22 2023-09-12 코오롱인더스트리 주식회사 가스켓 조립체 및 이를 포함하는 연료전지 가습기
CN113527300B (zh) * 2020-06-04 2023-02-03 广州百霆医药科技有限公司 布鲁顿酪氨酸蛋白激酶抑制剂
CN118434732A (zh) 2020-12-10 2024-08-02 建新公司 Tolebrutinib的晶型及其制备方法和用途
WO2022140511A1 (en) 2020-12-23 2022-06-30 Genzyme Corporation 4-amino-3-(4-phenoxyphenyl)-1,3- dihydro-2h-imidazo[4,5-c]pyridin-2-one derivatives and salts thereof
WO2022242740A1 (zh) * 2021-05-21 2022-11-24 杭州领业医药科技有限公司 Tolebrutinib盐及其晶型、其制备方法、其药物组合物和用途
US20250154149A1 (en) * 2022-02-16 2025-05-15 Betta Pharmaceuticals Co., Ltd. Pharmaceutical composition and method for preparing active ingredient compound thereof
JP2026509318A (ja) 2022-10-31 2026-03-18 スミトモ・ファーマ・アメリカ・インコーポレイテッド 骨髄増殖性新生物を治療するためのpim1阻害剤
CN117777134B (zh) * 2022-12-19 2025-02-25 艾立康药业股份有限公司 作为mat2a抑制剂的多环类化合物
WO2025218778A1 (zh) * 2024-04-19 2025-10-23 赛诺哈勃药业(成都)有限公司 杂环化合物及其作为ret抑制剂的用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US6326469B1 (en) 1994-04-22 2001-12-04 Sugen, Inc. Megakaryocytic protein tyrosine kinases
US7071199B1 (en) * 1999-09-17 2006-07-04 Abbott Gmbh & Cco. Kg Kinase inhibitors as therapeutic agents
WO2001019828A2 (en) * 1999-09-17 2001-03-22 Basf Aktiengesellschaft Kinase inhibitors as therapeutic agents
MXPA05005983A (es) * 2002-12-04 2005-08-18 Eisai Co Ltd Compuestos de anillo fusionado 1,3-dihidroimidazol.
WO2007035873A1 (en) * 2005-09-21 2007-03-29 Pharmacopeia, Inc. Purinone derivatives for treating neurodegenerative diseases
PL2526933T3 (pl) 2006-09-22 2015-08-31 Pharmacyclics Llc Inhibitory kinazy tyrozynowej Brutona
US20080119496A1 (en) 2006-11-16 2008-05-22 Pharmacopeia Drug Discovery, Inc. 7-Substituted Purine Derivatives for Immunosuppression
KR20100014271A (ko) * 2006-11-16 2010-02-10 파마코페이아, 엘엘씨. 면역 억제를 위한 7-치환된 퓨린 유도체
SG10201508035TA (en) * 2007-03-28 2015-10-29 Pharmacyclics Inc Inhibitors of bruton's tyrosine kinase
MX2012013622A (es) * 2010-05-31 2013-02-01 Ono Pharmaceutical Co Derivado de purinona.
US8501724B1 (en) * 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
US9637487B2 (en) * 2013-07-02 2017-05-02 Pharmacyclics Llc Purinone compounds as kinase inhibitors

Similar Documents

Publication Publication Date Title
JP2015509927A5 (enExample)
RU2018118216A (ru) Соединения пуринона в качестве ингибиторов киназ
JP2020530487A5 (enExample)
JP2020500178A5 (enExample)
JP2020169171A5 (enExample)
JP2024504932A5 (enExample)
JP2006516143A5 (enExample)
JP2022551185A5 (enExample)
JP2007528417A5 (enExample)
JP2007501859A5 (enExample)
JP2020532545A5 (enExample)
JP2022507474A5 (enExample)
JP2016526558A5 (enExample)
JP2021516237A5 (enExample)
JP2012507522A5 (enExample)
JP2023553835A5 (enExample)
JP6639446B2 (ja) 液晶混合物の製造方法
JP2013504593A5 (enExample)
RU2017117562A (ru) Лекарственные средства на основе лантионинсинтетаза с-подобного белка
JP6341923B2 (ja) 強蛍光発光性の複素環化合物及びその製造方法
JP2015524019A5 (enExample)
WO2006022252A1 (ja) アミノチアゾール誘導体の製造法及び製造中間体
JP2008540454A5 (enExample)
RU2019115059A (ru) Модуляторы ror-гамма
US10196411B2 (en) Tizoxanide phosphate and alkane sulfonate and pharmaceutical applications thereof